The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Open Access
- 4 September 2007
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 117 (9), 2649-2657
- https://doi.org/10.1172/jci32338
Abstract
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.Keywords
This publication has 43 references indexed in Scilit:
- Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral MucormycosisAntimicrobial Agents and Chemotherapy, 2006
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood, 2006
- Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patientsBone Marrow Transplantation, 2006
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005
- Orchestration of Iron HomeostasisNew England Journal of Medicine, 2005
- A phagocytic cell line markedly improves survival of infected neutropenic miceJournal of Leukocyte Biology, 2005
- Iron and microbial infectionNature Reviews Microbiology, 2004
- Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene*1FEMS Microbiology Letters, 2004
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003
- Role of iron in T cell activation: Th1 clones differ from TH2 clones in their sensitivity to inhibition of DNA synthesis caused by IGG mabs against the transferrin receptor and the iron chelator deferoxamineCellular Immunology, 1991